source
- Italian biotech sector gains traction as venture capital and tech transfer improvements boost startupsItaly has long been recognized for its high‑quality scientific research, yet converting that output into successful biotech startups has been a persistent challenge. Recent years have seen a shift…
- J&J returns rights to lymphoma CAR‑T therapy prizlon‑cel to AbelZetaJohnson & Johnson secured exclusive rights to the bispecific CAR T candidate prizlon‑cel in 2023, paying an upfront $245 million. The therapy, designed for large B‑cell lymphoma, achieved a 100% r…